Featured Story | By Annalee Armstrong Biogen’s non-opioid pain therapy did not reduce average daily pain as intended during a midstage study, but patients did report an overall improvement in the pain they experience. read more |
| |
|---|
|
Top Stories By Ben Adams Aerie Pharmaceuticals earned the ire of Bio Twitter and its investors Wednesday night after it dropped a failed midstage study after-hours, but whitewashed the flop and said it would still push on with a phase 3. read more By Nick Paul Taylor Herceptin’s long-lasting dominance of the gastroesophageal cancer market may be under threat. At the European Society of Medical Oncology Congress 2021, Zymeworks presented encouraging early data on its HER2‑targeted bispecific antibody—and a showdown with the incumbent is up next. read more Sponsored by: IQVIA Are you using data and analytics to design smarter campaigns and more effective sales rep deployment? read more By Annalee Armstrong Intellia's application to kick start a trial for an ex vivo CRISPR genome editing cancer candidate has been accepted by the FDA. The biotech plans to start screening patients for a phase 1/2a study by the end of the year. read more By Amirah Al Idrus IASO Biotherapeutics bagged $108 million to fuel a teeming pipeline of cell therapies and antibodies for cancer and autoimmune disease. The series C round brings the company’s total raised to more than $178 million. read more By Nick Paul Taylor In 2017, Joël de Beer dropped out of his Ph.D. program and began trying to build a leading genetic medicines company from a site the size of a parking space. After working quietly for several years to realize the vision, de Beer’s Anjarium Biosciences has now broken cover with 55.5 million Swiss francs from top-tier investors including Abingworth, Gimv and Pfizer Ventures. read more By Kyle LaHucik Amolyt Pharma secured an $80 million series B to advance three core programs and build up its earlier-stage pipeline. The French biotech is backed by Novo Holdings, Mass General Brigham Ventures and other cross-continental venture groups. read more By Andrea Park Deciphering the inner workings of the brain to get to the root of neurological conditions like Parkinson’s disease and multiple sclerosis is a lot like translating ancient writing systems into our modern languages—but the aptly named Rune Labs is on the case. read more By Angus Liu It’s almost an unspoken rule in the biopharma industry that companies seldom compare two drugs with similar mechanisms of action side by side in the same study. But Bayer decided to go for a comparison of its “tumor agnostic” cancer drug Vitrakvi, though indirectly. read more By Robert King Several venture capital funds warned that funding for new drugs would quickly dry up if Democrats give Medicare far-reaching drug price negotiation powers in a $3.5 trillion infrastructure package. read more |  | The life-changing potential of cell & gene therapy demands lab services that are just as transformative. LabConnect® leads the evolution of lab services with customized solutions that simplify clinical trial complexity. Let us help with your next study so you can focus on the research. Learn more. |
Resources Sponsored By: Unlearn AI Read Unlearn’s whitepaper to learn about how novel trial designs with Digital Twins enable more efficient clinical trials, with higher power and smaller required sample sizes. Sponsored by: Patheon by Thermo Fisher Scientific Choose the right AAV platform for your viral vector-based therapy Sponsored by: XIFIN inc. Download the Value of Precision Medicine Informatics (PMI) Initiatives report to learn about the technology, data types, and the value derived from more than 100 PMI initiatives. Sponsored by: EVERSANA Today’s economics do not allow manufactures to keep making decisions in an antiquated way. They need to challenge tradition & deliver faster, cheaper, successful launches. Learn how. Sponsored by: Thermo Fisher Scientific Thermo Fisher Scientific introduces a new NK cell culture medium designed to support feeder-free, high-yield growth for cell therapy applications. Sponsored by: Cascade Chemistry by Aceto Read four customer success stories and four success factors that helped move pharmaceutical customers of Cascade Chemistry by Aceto quickly and effectively to clinic with trial-ready APIs. Sponsored by: ConnectiveRx Topple barriers to getting patients started on therapy. Guide them with mobile. Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. | 
